TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
26/02/2024
Voltar para busca
Dado oficial do USPTO
SYNENDOS
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
SYNENDOS
ST13
US500000079330074Classe
5, 42, 44
Pedido
79330074
Registro
7141186
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
38
Atualização mais recente
26/02/2024
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 42, 44
Data de depósito
10/11/2021
Data de registro
22/08/2023
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
22/08/2023
Última transação
26/02/2024
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
25
Localização do titular
CH
Examinador
MANCA, ALBERTO I
Unidade examinadora
L80
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Synendos Therapeutics AG
Representantes
Catherine F. Hoffman Baker, Donelson, Bearman, Caldwell, & Berkowitz, PC
Classificação técnica
Classes Nice
Classe 5Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical products for the treatment of neuropsychiatricneurological and psychiatric diseases and disorders; pharmaceutical products for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalrenalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatricinflammatoryimmuneautoimmunegenetic diseases and disorders; medical preparations and substances for the treatment of neuropsychiatricneurological and psychiatric diseases and disorders; medical preparations and substances for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalrenalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatricinflammatoryimmuneautoimmunegenetic diseases and disorders; veterinary preparations and substances for the treatment of neuropsychiatricneurological and psychiatric diseases and disorders; veterinary preparations and substances for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalrenalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatricinflammatoryimmuneautoimmunegenetic diseases and disorders; sanitary preparations for medical use; medicines for pharmaceutical use for the treatment of neuropsychiatricneurological and psychiatric diseases and disorders; medicines for pharmaceutical use for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalrenalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatricinflammatoryimmuneautoimmunegenetic diseases and disorders; medicines for human medicine for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalrenalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatricinflammatoryimmuneautoimmunegenetic diseases and disorders; medicines for human medicinepharmaceutical preparations acting on the central nervous systembiopharmaceutical preparations acting on the central nervous systempharmaceutical agents affecting the peripheral nervous system and biopharmaceutical agents affecting the peripheral nervous system; medicines for human medicinemedicines for treating biochemical imbalances in vivo; chemical-pharmaceutical preparationspharmaceutical preparations acting on the central nervous systembiopharmaceutical preparations acting on the central nervous systempharmaceutical agents affecting the peripheral nervous system and biopharmaceutical agents affecting the peripheral nervous system; chemical preparations for medical usepharmaceutical preparations acting on the central nervous systembiopharmaceutical preparations acting on the central nervous systempharmaceutical agents affecting the peripheral nervous system and biopharmaceutical agents affecting the peripheral nervous system; chemical preparations for pharmaceutical usepharmaceutical preparations acting on the central nervous systembiopharmaceutical preparations acting on the central nervous systempharmaceutical agents affecting the peripheral nervous system and biopharmaceutical agents affecting the peripheral nervous system; chemical preparations for veterinary usepharmaceutical preparations acting on the central nervous systembiopharmaceutical preparations acting on the central nervous systempharmaceutical agents affecting the peripheral nervous system and biopharmaceutical agents affecting the peripheral nervous system; chemical preparations for medical use for treating biochemical imbalances in vivo; chemical preparations for veterinary use for treating biochemical imbalances in vivo; diagnostic substancespreparations and agents for medical use
Classe 42
Scientific and technological servicesscientific researchanalysistesting in the fields of pharmaceuticalsbiopharmaceuticalschemistrybiologybiochemistry; industrial analysis servicesindustrial analysis in the fields of pharmaceuticalsbiopharmaceuticals; industrial research services in the fields of pharmaceuticalsbiopharmaceuticals; scientific research and development; scientific research; scientific analysisbiological analysisbiochemical analysischemical analysis; conducting chemical and biological analyses for scientific purposes; conducting medical analysis for scientific purposesbiological analysisbiochemical analysischemical analysisblood analysis; medical research; pharmaceutical research; research in the fields of chemistry and biology; biotechnological research services; providing medical and scientific research informationproviding information and data with respect to medical and veterinary research and development; providing information with respect to medical and scientific research in the field of pharmaceutical products; providing scientific information on research in the field of pharmaceutical products and biomedicine
Classe 44
Medical services; veterinary services; hygienic care for human beings; medical and pharmaceutical consultancy services; medical tests for diagnostic or treatment purposes; conducting of medical examinations; consultations regarding pharmacology; pharmaceutical consultingconsultant and information services relating to pharmaceutical products; conducting of chemicalmedical and biological analyses for medical diagnosis being medical diagnostic testing services; consultancy and information services relating to medical products being pharmaceutical consultation services; medical analysis services relating to the treatment of patients; medical consultancy services; pharmacy advice being pharmaceutical consultation
Publicações
Histórico de despachos e eventos da marca no USPTO.
38 publicações encontradas
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
26/02/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
26/02/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
26/02/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
26/02/2024
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
11/12/2023
FICS
FINAL DISPOSITION NOTICE SENT TO IB
22/11/2023
FIMP
FINAL DISPOSITION PROCESSED
22/11/2023
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
22/11/2023
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
22/08/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
22/08/2023
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
19/06/2023
GPNX
NOTIFICATION PROCESSED BY IB
06/06/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
06/06/2023
PUBO
PUBLISHED FOR OPPOSITION
06/06/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
31/05/2023
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
31/05/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
17/05/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
17/05/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
17/05/2023
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
06/05/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/05/2023
XAEC
EXAMINER'S AMENDMENT ENTERED
01/05/2023
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
01/05/2023
GNEA
EXAMINERS AMENDMENT E-MAILED
01/05/2023
CNEA
EXAMINERS AMENDMENT -WRITTEN
01/05/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
30/03/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
30/03/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
30/03/2023
RFNT
REFUSAL PROCESSED BY IB
25/10/2022
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
01/10/2022
RFRR
REFUSAL PROCESSED BY MPU
01/10/2022
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
25/08/2022
CNRT
NON-FINAL ACTION WRITTEN
24/08/2022
DOCK
ASSIGNED TO EXAMINER
22/08/2022
MAFR
APPLICATION FILING RECEIPT MAILED
08/01/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/01/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
30/12/2021
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace SYNENDOS ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.